Cell structure and experimental cardiac biology
3Scope of investigation or explicitly identified community interest; not an established indication.
Recovery
Cardiogen
AEDR cell-signaling research
Lab studiesHeart-cell biology3
Investigational; this profile does not establish an approved use.
What does it do?
AEDR tetrapeptide bioregulator investigated in cardiac cells and animals; human clinical efficacy is unestablished.
Approved & studied uses
Community uses Reported, unvalidated
Cardiovascular
12Cardiac tissue, injury remodeling and age-related decline; oral heart-disease/hypertension/failure claims are manufacturer/practice reports.
Cellular
12Actin/vimentin/tubulin, lamin proteins and apoptosis.
Aging
12Tissue maintenance and multi-bioregulator longevity claims.
Reasons people report using it; these do not establish benefit.12
Evidence limits
View research →Human cardiovascular benefit, dosing and long-term safety were not established in the verified research.3
3 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Cardiac claims
The checked fibroblast experiment cannot establish heart-disease benefit or cardiovascular safety.3
Investigational; this profile does not establish an approved use.
Amino-acid sequence
- Ala
- Glu
- Asp
- Arg
4 residues · N → C3
Reference identity · not independently confirmed12
Length4 amino acids
Molecular weight · Da489.47 Da
Formula, sequence notation & identity
A–E–D–RAla–Glu–Asp–Arg (AEDR)
Sequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.
Pep-Pedia identity details
4 amino acids · 489.47 Da
Ala-Glu-Asp-Arg (AEDR)Reference description; checked chemical identity above takes precedence when available.12
Pharmacokinetics
How long does it stay in the body?
Reported half-lifeHuman kinetics not established3
No numerical human elimination estimate is assigned from animal experiments, related molecules, or an unsupported website estimate.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
What to expect
Study outcomes
Scope of evidence
Human cardiovascular benefit, dosing and long-term safety were not established in the verified research.3
Reported timelines
Reference & communityWeeks 1–2 / 2–4 / month 1
Reference: little observable change, cellular/cumulative effects. No established human efficacy timeline.12
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Primary goal
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Effectiveness
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Source & limitations
The source displays “46 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQ | 10 mg | Every 3-7 days | Standard Protocol (Community-Derived)Reference report | 2-4 weeks | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 20 mg | Every 3-7 days | Intensive Protocol (Community-Derived)Reference report | 2-4 weeks | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 10-20 mg | Weekly for up to 16 weeks | Extended Cycle (Community-Derived)Reference report | 2-4 weeks | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| Oral | 2 capsules (200 mcg) | Once daily before meals | Standard Cardiovascular SupportReference report | 1 month | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| Oral | 2 capsules (200 mcg) | Twice daily before meals | Intensive ProtocolReference report | 1 month | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| Oral | 2 capsules (200 mcg) | Once daily for 1 month, repeat after 3-6 months | Repeat CourseReference report | 1 month | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 2-4 weeks
- Break
- 3-6 months between cycles
Reported timing
Morning administration
Oral
- Use period
- 1 month
- Break
- 3-6 months between courses
Reported timing
Before breakfast and/or dinner
Side effects & safety
Cardiac claims
The checked fibroblast experiment cannot establish heart-disease benefit or cardiovascular safety.
3Unverified human dosing
The community’s 10–20 mg schedules are not supported by a verified human dose-finding study.
3Symptoms
Chest pain, palpitations, breathlessness, persistent digestive/injection problems, infection or allergy need assessment.
Proliferation
Cancer-related concerns theoretical; pregnancy/lactation safety unknown.
Evidence
Oral absorption and manufacturer safety claims unvalidated.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Cardiovascular medications
Caution reportedNo blanket compatibility.12
Reference report · Pep-Pedia label: Monitor CombinationIGF-1 / HGH
Caution reportedProliferation overlap.12
Reference report · Pep-Pedia label: Monitor CombinationBPC-157
Unverified pairingNo combination studies.12
Reference report · Pep-Pedia label: SynergisticTB-500
Unverified pairingNo combination studies.12
Reference report · Pep-Pedia label: SynergisticPinealon
Unverified pairingDifferent tissue targets.12
Reference report · Pep-Pedia label: CompatibleCartalax
Unverified pairingDifferent tissue targets.12
Reference report · Pep-Pedia label: CompatibleThymosin alpha-1
Unverified pairingDifferent tissue targets.12
Reference report · Pep-Pedia label: CompatibleEpitalon
Unverified pairingLongevity rationale.12
Reference report · Pep-Pedia label: SynergisticOther peptides and medicines
Not establishedA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.4
Research contextNo matching interactions. Try another name or filter.
Reconstitution
A product-specific preparation or sterility protocol has not been verified.4
Dilution
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.4
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Source temperature: 2-8°C. · The source specifies protection from light.
The source describes gentle mixing and avoiding vigorous shaking.
Oral
The oral section describes capsules taken before meals.
- Form
- Source describes a prepared product
- Reported parameters
- Reported course: 1 month, with 3–6 months before repetition. · Capsules: cool, dry room-temperature storage.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite Lyophilized PowderReported appearanceClear Reconstituted SolutionReported appearanceCertificate of AnalysisReported variationResearch Use OnlyReported concernDiscolored or Cloudy Solution
12Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
12Refrigerate at 2-8°C, use within 30 days after reconstitution
Room temperature, cool dry place
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
PreclinicalCompound identity & other names
Cardiogen is the AEDR tetrapeptide. Its cited work concerns cell biology and experimental tissue models; the name should not be read as evidence of a heart-health treatment.
Other names: AEDR
Investigational; this profile does not establish an approved use.
How it may work
Proposed fibroblast, p53, cytoskeletal and nuclear-matrix regulation.12
Protein expression in mouse cells
The study reported approximately 2–5-fold changes in cytoskeletal and 2–3-fold changes in nuclear-matrix protein expression. It did not test treatment of heart disease.
3Research areas and evidence gaps
Cell structure and experimental cardiac biology. Scope of investigation or explicitly identified community interest; not an established indication.3
- Human cardiovascular benefit, dosing and long-term safety were not established in the verified research.
- The evidence does not validate the identity, purity or handling of a separately sourced research product.
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.4
Community protocol tables are unvalidated descriptions, not treatment instructions.
Search coverage and review status
Additional primary or regulatory sources were checked. No further 2025–2026 exact-compound clinical outcome study was identified in this targeted search; this is not evidence that none exists.
- Checked
- 2026-10-12
- Search
- Cardiogen Ala Glu Asp Arg 2025 2026 study PubMed
- Catalog
- Pep-Pedia ↗ · 9 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Tetrapeptide H-Ala-Glu-Asp-Arg-OH Stimulates Expression of Cytoskeletal and Nuclear Matrix ProteinsAbstract checked
AI-PREPARED SUMMARY
AEDR altered protein expression in cultured mouse embryonic fibroblasts. Human cardiac benefit was not tested.
Pep-Pedia bibliography · Checked 2026-10-12
2Tetrapeptide H-Ala-Glu-Asp-Arg-OH Stimulates Expression of Cytoskeletal and Nuclear Matrix ProteinsAbstract checked
AI-PREPARED SUMMARY
AEDR altered protein expression in cultured mouse embryonic fibroblasts. Human cardiac benefit was not tested.
Pep-Pedia bibliography · Checked 2026-10-12
3Tetrapeptide H-Ala-Glu-Asp-Arg-OH Stimulates Expression of Cytoskeletal and Nuclear Matrix ProteinsAbstract checked
AI-PREPARED SUMMARY
AEDR altered protein expression in cultured mouse embryonic fibroblasts. Human cardiac benefit was not tested.
Protein expression in mouse cells
The study reported approximately 2–5-fold changes in cytoskeletal and 2–3-fold changes in nuclear-matrix protein expression. It did not test treatment of heart disease.
Additional research · Checked 2026-10-12
4Pep-Pedia: CardiogenCommunity source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
5Chalisova, N.I., Lesniak, V.V., Balykina, N.A., Urt'eva, S.A., Urt'eva, T.A., Sukhonos, Yu.A., Zhekalov, A.N. (2009). The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats. Advances in Gerontology, 22(3), 409-413.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Young and old rat heart cultures showed greater proliferation and lower p53 expression after peptide exposure.
Reported population / model
Rat myocardial tissue
Reported study details
Young (3-month) and old (24-month) · Various concentrations · Proliferation stimulation
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Levdik, N.V., Knyazkin, I.V. (2009). Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bulletin of Experimental Biology and Medicine, 148(3), 433-436.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The rat sarcoma model showed dose-related growth suppression associated with vascular disruption, bleeding and tumor-cell death.
Reported population / model
Senescent rats
Reported study details
M-1 sarcoma model · Multiple doses · Dose-dependent tumor inhibition
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Zakutskii, A.N., Chalisova, N.I., Ryzhak, G.A., Aniskina, A.I., Filippov, S.V., Zeziulin, P.N. (2006). The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. Advances in Gerontology, 19, 93-96.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Heart cultures responded at 0.05 ng/mL in an organ-culture experiment involving several different tissue-targeted peptides.
Reported population / model
Rats (young 3-week and aged 18-month)
Reported study details
Heart, lung, prostate, pancreatic tissue · 0.05 ng/ml · Tissue-specific stimulation
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Kheifets, O.V., Polyakova, V.O., Kvetnoy, I.M. (2010). Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging. Advances in Gerontology, 23(1), 68-70.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Aging fibroblast cultures showed higher CXCL12, WEDC1 and ghrelin expression, approaching young-control values.
Reported population / model
Human prostate fibroblasts
Reported study details
Cell aging model · Peptide treatment · Enhanced CXCL12, WEDC1, ghrelin
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Coronary Artery Ligation Mouse ModelPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source claims roughly threefold lower mortality after coronary ligation in treated mice; a linked primary report is needed to assess this claim.
Reported population / model
Mouse
Reported study details
Coronary artery ligation · AEDR treatment · Threefold mortality reduction
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Khavinson, V.Kh. (2002). Peptides and aging. Neuroendocrinology Letters, 23(Suppl 3), 11-144.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
11Levdik, N.V., Knyazkin, I.V. (2009). Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bulletin of Experimental Biology and Medicine, 148(3), 433-436.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
12Pep-Pedia: Cardiogen — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12